Syndax Pharmaceuticals Inc
NASDAQ:SNDX

Watchlist Manager
Syndax Pharmaceuticals Inc Logo
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
Watchlist
Price: 10.65 USD 0.76% Market Closed
Market Cap: 916.3m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+33%
Revenue
Forecast
0%
Operating Income
Forecast
+10%
Net Income
Forecast
+89%

Wall Street
Price Targets

SNDX Price Targets Summary
Syndax Pharmaceuticals Inc

Wall Street analysts forecast SNDX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SNDX is 35.51 USD with a low forecast of 16.16 USD and a high forecast of 53.55 USD.

SNDX Lowest Forecast
Wall Street Target
16.16 USD
52% Upside
SNDX Average Forecast
Wall Street Target
35.51 USD
233% Upside
SNDX Highest Forecast
Wall Street Target
53.55 USD
403% Upside
Lowest
Price Target
16.16 USD
52% Upside
Average
Price Target
35.51 USD
233% Upside
Highest
Price Target
53.55 USD
403% Upside
Syndax Pharmaceuticals Inc Competitors:
Price Targets
302440
SK Bioscience Co Ltd
6% Upside
BPMC
Blueprint Medicines Corp
26% Upside
BSLN
Basilea Pharmaceutica AG
100% Upside
CUV
Clinuvel Pharmaceuticals Ltd
152% Upside
302440
SK Bioscience Co Ltd
6% Upside
BPMC
Blueprint Medicines Corp
26% Upside
BSLN
Basilea Pharmaceutica AG
100% Upside
CUV
Clinuvel Pharmaceuticals Ltd
152% Upside
I
IVACC
Intervacc AB
553% Upside
002007
Hualan Biological Engineering Inc
20% Upside
IGMS
IGM Biosciences Inc
62% Upside
IDYA
IDEAYA Biosciences Inc
175% Upside

Revenue
Forecast

Revenue Estimate
Syndax Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Syndax Pharmaceuticals Inc's revenue is 45%. The projected CAGR for the next 3 years is 143%.

45%
Past Growth
143%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Syndax Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Syndax Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-59%
Average Miss
What are analyst estimates?

See Also

Summary
SNDX intrinsic value, competitors valuation, and company profile.
DCF Valuation
SNDX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SNDX stock valuation using valuation multiples.
Wall Street Estimates
SNDX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SNDX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SNDX's stock price target?
Price Target
35.51 USD

According to Wall Street analysts, the average 1-year price target for SNDX is 35.51 USD with a low forecast of 16.16 USD and a high forecast of 53.55 USD.

What is Syndax Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
143%

For the last 8 years the compound annual growth rate for Syndax Pharmaceuticals Inc's revenue is 45%. The projected CAGR for the next 3 years is 143%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 256,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.